Global Targeted Protein Degradation Beyond PROTACs (LYTACs/AUTACs) Market Strategic Research Report

The global targeted protein degradation (TPD) market beyond PROTACs — encompassing lysosome-targeting chimaeras (LYTACs), autophagy-targeting chimaeras (AUTACs), molecular glue degraders, ATTEC (autophagosome-tethering compound) platforms, and related next-generation modalities — represented an estimated USD 1.8 billion in combined research investment, licensing revenue, and early commercial activity in 2024. This segment of the broader TPD landscape has emerged as one of the most scientifically consequential areas of drug discovery in the past decade, addressing the fundamental limitation of conventional small-molecule therapeutics: the inability to degrade extracellular proteins, membrane receptors, and aggregation-prone species that are implicated in oncology, neurodegeneration, and metabolic disease. The commercial momentum is underpinned by a wave of venture capital financing, major pharma licensing deals exceeding USD 500 million in individual upfront payments, and the entry of dedicated platform companies into early clinical development, establishing this as a credible inflection point for the field.

Three forces are driving investment and development activity with particular intensity. First, the addressable target space for LYTAC and AUTAC platforms extends to roughly 40 percent of the human proteome that is inaccessible to classical PROTAC technology, including secreted proteins and cell-surface receptors that drive resistance mechanisms in oncology — a scientific rationale that commands premium licensing valuations from large pharmaceutical partners. Second, accelerating structural biology and cryo-EM capabilities have compressed the rational design cycle for ternary complex formation, reducing lead optimization timelines and improving the probability of technical success for platform-based approaches. Third, the maturation of antibody–LYTAC conjugation chemistry and AUTAC warhead libraries is enabling degraders to address neurological targets such as tau aggregates and alpha-synuclein, opening a disease category historically resistant to small-molecule intervention. A meaningful restraint on near-term commercial translation is the limited clinical validation of non-PROTAC modalities; as of 2024, only a small number of LYTAC-based candidates have entered Phase I trials, sustaining pharmacokinetic and in vivo efficacy uncertainty that tempering deal structures and timelines.

This report provides a comprehensive quantitative and qualitative analysis of the global TPD-beyond-PROTACs market across the 2025–2032 forecast horizon, segmented by degrader modality, application therapeutic area, and geography. It profiles ten leading platform and pharmaceutical companies, maps competitive positioning, and evaluates M&A and partnership activity through early 2025. The report is designed for corporate strategy teams evaluating platform acquisitions, investment analysts assessing pipeline risk-adjusted valuations, M&A advisors benchmarking deal structures, and procurement managers at CROs and CDMOs building TPD service capabilities.